Bausch and Lomb

News

Bausch + Lomb drug fails in glaucoma, but a new use beckons

Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.

News

Bausch + Lomb dips on rumour of failing takeover talks

Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.

News

Bausch + Lomb buys US rights to Stada's Lucentis biosimilar

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte

Bausch + Lomb drug fails in glaucoma, but a new use beckons

Bausch + Lomb dips on rumour of failing takeover talks

Bausch + Lomb buys US rights to Stada's Lucentis biosimilar

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks